<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020279</url>
  </required_header>
  <id_info>
    <org_study_id>XPM-023</org_study_id>
    <nct_id>NCT01020279</nct_id>
  </id_info>
  <brief_title>Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise</brief_title>
  <official_title>Multiple-dose, Randomized, Subject and Observer Blinded, Placebo-controlled, Double-dummy Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>X-pert Med GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>X-pert Med GmbH</source>
  <brief_summary>
    <textblock>
      1. Comparison of the effect of ketoprofen Transfersome® gel (KTG) to placebo gel (PG) on&#xD;
           muscle pain of the calf caused by eccentric contractions&#xD;
&#xD;
        2. Comparison of the effect of KTG to celecoxib (CE) on muscle pain of the calf caused by&#xD;
           eccentric contractions&#xD;
&#xD;
        3. Comparison of the effect of celecoxib (CE) to oral placebo (OP) on muscle pain of the&#xD;
           calf caused by eccentric contractions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain during muscle contraction</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain during rest</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surface temperature</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of the lower leg</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Parallel Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib, Ketoprofen</intervention_name>
    <description>Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.&#xD;
Celecoxib, 200 mg, one capsule b.i.d.</description>
    <arm_group_label>Parallel Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <description>Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d</description>
    <arm_group_label>Parallel Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent prior to participation&#xD;
&#xD;
          -  Subjects in good health as determined by the Investigator&#xD;
&#xD;
          -  Age 18-55&#xD;
&#xD;
          -  Willing to abstain from any physical therapy, hard physical work, exercise or sauna&#xD;
             during the study observation period (Screening to Final Visit)&#xD;
&#xD;
          -  For females, subjects of childbearing potential (including peri-menopausal women who&#xD;
             have had a menstrual period within 1 year) must be using appropriate birth control&#xD;
             (defined as a method which results in a low failure rate, i.e., less than 1% per year&#xD;
             when used consistently and correctly, such as implants, injectables, some intrauterine&#xD;
             contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral&#xD;
             contraceptive medications are allowed in this study. Female subjects, who are&#xD;
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)&#xD;
             are also allowed for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study within the last 30 days and during the study&#xD;
&#xD;
          -  Subjects who are inmates of psychiatric wards, prisons, or other state institutions&#xD;
&#xD;
          -  Investigator or any other team member involved directly or indirectly in the conduct&#xD;
             of the clinical study&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Malignancy within the past 2 years with the exception of in situ removal of basal cell&#xD;
             carcinoma&#xD;
&#xD;
          -  Skin lesions, dermatological diseases or tattoo in the treatment areas&#xD;
&#xD;
          -  Known hypersensitivity or allergy (including photoallergy) to NSAID´s including&#xD;
             celecoxib, sulfonamides and ingredients used in pharmaceutical products and cosmetics&#xD;
             including galactose&#xD;
&#xD;
          -  Varicosis, thrombophlebitis and other vascular disorders of the lower extremities&#xD;
&#xD;
          -  Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the&#xD;
             musculo-skeletal system of the lower limbs&#xD;
&#xD;
          -  Pain conditions which might interfere with pain rating during the study, e.g.&#xD;
             neuropathic pain&#xD;
&#xD;
          -  Significant neurological or psychiatric symptoms resulting in disorientation, memory&#xD;
             impairment, or inability to report accurately (e.g. Alzheimer's disease or&#xD;
             schizophrenia or other psychosis), that in the investigator's opinion may affect&#xD;
             efficacy or safety assessments or may compromise subject safety during the study&#xD;
&#xD;
          -  Systemic lupus erythematodes, mixed connective tissue disease&#xD;
&#xD;
          -  Major heart disease / uncontrollable hypertension&#xD;
&#xD;
          -  Peripheral arterial disease and/or cerebrovascular disease&#xD;
&#xD;
          -  History of stroke or myocardial infarction&#xD;
&#xD;
          -  GFR &lt; 30 ml/min&#xD;
&#xD;
          -  ALT and/or AST levels ≥ 5 times the ULN&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease including asthma bronchiale&#xD;
&#xD;
          -  Coagulopathy or bleeding diathesis, or concomitant use of anticoagulants including low&#xD;
             dose aspirin&#xD;
&#xD;
          -  History of pancreatitis or peptic ulcers&#xD;
&#xD;
          -  Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)&#xD;
&#xD;
          -  Reflux esophagitis requiring treatment&#xD;
&#xD;
          -  Any other analgesic therapy including cough and cold drugs containing analgesic&#xD;
             properties as well as any other substance used for the treatment of pain during the&#xD;
             study observation period (Screening to final Visit)&#xD;
&#xD;
          -  Any other drug that might alter pain perception like CNS active drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>X-pert Med GmbH</name>
      <address>
        <city>Jena</city>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dipl. med. Ilka Rother</name_title>
    <organization>X-pert Med GmbH</organization>
  </responsible_party>
  <keyword>muscle pain</keyword>
  <keyword>model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

